US 12,466,889 B2
Anti-HLA-G antibodies and use thereof
Alexander Bujotzek, Munich (DE); Alejandro Carpy Gutierrez Cirlos, Munich (DE); Anne Freimoser-Grundschober, Zurich (CH); Carina Hage, Penzberg (DE); Thomas Hofer, Zurich (CH); Silke Kirchner, Penzberg (DE); Meher Majety, Munich (DE); Ekkehard Moessner, Kreuzlingen (CH); Christiane Neumann, Schlieren (CH); Christian Spick, Seeshaupt (DE); Georg Tiefenthaler, Sindelsdorf (DE); and Thomas Weindl, Lenggries (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Oct. 18, 2022, as Appl. No. 18/047,605.
Application 18/047,605 is a continuation of application No. 17/644,525, filed on Dec. 15, 2021.
Claims priority of application No. 20214951 (EP), filed on Dec. 17, 2020; and application No. 21203272 (EP), filed on Oct. 18, 2021.
Prior Publication US 2023/0159642 A1, May 25, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2833 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)] 91 Claims
OG exemplary drawing
 
1. A bispecific antibody that binds to human HLA-G and human CD3, comprising:
a first antigen binding moiety that binds to human HLA-G and comprises:
A) (a) a heavy chain variable (VH) domain comprising (i) heavy chain complementarity determining region (CDR) 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:1, (ii) heavy chain CDR 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:2, and (iii) heavy chain CDR 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:3; and (b) a light chain variable (VL) domain comprising (i) light chain CDR 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:23, (ii) light chain CDR 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:5, and (iii) light chain CDR 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6; or
B) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:25, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; and
a second antigen binding moiety that binds to human CD3 and comprises:
C) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:52, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:53, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:54; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:55, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:56, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:57;
D) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:61, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:65; or
E) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:68, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:69, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:70; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:71, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:72, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:73.